Promote Quadra™

Cardiac Resynchronisation Therapy Defibrillator (CRT-D)

Merlin@home™ Transmitter Compatible

Product Highlights

- The Promote Quadra CRT-D and Quartet™ quadripolar LV pacing lead feature four pacing electrodes and 10 pacing vectors to provide more options and greater control to minimise implant complications such as diaphragmatic stimulation and high pacing thresholds
- VectSelect Quartet™ programmable LV pulse configuration (Distal Tip 1 - Mid 2, Distal Tip 1 - Proximal 4, Distal Tip 1 - RV Coil, Mid 2 - Proximal 4, Mid 2 - RV Coil, Mid 3 - Mid 2, Mid 3 - Proximal 4, Mid 3 - RV Coil, Proximal 4 - Mid 2, Proximal 4 - RV Coil) may be adjusted noninvasively via the programmer
- The CorVue™ congestion monitoring feature monitors the intrathoracic impedance in multiple vectors for improved accuracy, and it provides the option for both patient and physician alerts
- 40 J delivered energy provides unsurpassed energy for defibrillation
- Dual DF4 header option for defibrillation lead (DF4-LLHH) and LV pacing lead (IS4-LLLL) reduce pocket bulk
- QHR™* chemistry battery provides greater capacity for enhanced longevity and charge times
- Triggered pacing with BiV™ Trigger Mode helps maintain a high percentage of BiV pacing by triggering pacing in both the left and right ventricles in response to a sensed ventricular event
- Negative AV hysteresis with search promotes ventricular pacing by automatically reducing the AV delay when intrinsic activity is present, thereby promoting a high degree of ventricular pacing

Ordering Information

Contents: Cardiac pulse generator

Model Number	Dimensions (H x W x T, mm)	Weight (g)	Volume (cc)	Connector Defibrillation	Connector Sense/Pace
CD3239-40	81 x 51 x 14	88	46	DF1	IS-1
CD3239-40Q	74 x 51 x 14	87	44	DF4	IS-1; DF4

Indications: The devices are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. Cardiac Resynchronisation Therapy devices (CRT-Ds) are also intended to resynchronise the right and left ventricles in patients with congestive heart failure.

Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance or acute myocardial infarction.

Adverse Events:
Implantation of the pulse generator system, like that of any other device, involves risks, some possibly life-threatening. These include but are not limited to the following: acute hemorrhage/bleeding, air emboli, arrhythmia acceleration, cardiac or venous perforation, cardiogenic shock, cyst formation, erosion, exacerbation of heart failure, extrusion, fibrotic tissue growth, fluid accumulation, hematoma formation, histotoxic reactions, infection, keloid formation, myocardial irritability, nerve damage, pneumothorax, thromboemboli, venous occlusion. Other possible adverse effects include mortality due to: component failure, device-programmer communication failure, lead abrasion, lead dislodgment or poor lead placement, lead fracture, inability to defibrillate, inhibited therapy for a ventricular tachycardia, interruption of function due to electrical or magnetic interference, shunting of energy from defibrillation paddles, system failure due to ionising radiation. Other possible adverse effects include mortality due to inappropriate delivery of therapy caused by: multiple counting of cardiac events including T-waves, P-waves or supplemental pacemaker stimuli. Among the psychological effects of device implantation are imagined pulsing, dependency, fear of inappropriate pulsing and fear of losing pulse capability.

Refer to the User's Manual for detailed indications, contraindications, warnings, precautions and potential adverse events.

Customer Support: 46-8-474-4756

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Devices depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability in your country. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies.

ST. JUDE MEDICAL
MORE CONTROL. LESS RISK.

Promote Quadra™

Cardiac Resynchronisation Therapy Defibrillator (CRT-D)

Product Specifications

PHYSICAL SPECIFICATIONS		
Models	**CD3239-40**	**CD3239-40Q**
Telemetry	RF	RF
Delivered Energy (J)	40	40
Volume (cc)	46	44
Weight (g)	88	87
Size (mm)	81x51x14	74x51x14
Defibrillation Lead Connections	DF1	DF4-LLHH
LV Lead Connections	IS4-LLLL	IS4-LLLL
Sense/Pace Lead Connections	IS-1	IS-1
High-Voltage Can	Electrically active titanium can	Electrically active titanium can

PARAMETER	SETTINGS
Biventricular Pacing	
VectSelect Quartet™ LV Pulse Configuration	Distal Tip 1 - Mid 2; Distal Tip 1 - Proximal 4; Distal Tip 1 - RV Coil; Mid 2 - Proximal 4; Mid 2 - RV Coil; Mid 3 - Mid 2; Mid 3 - Proximal 4; Mid 3 - RV Coil; Proximal 4 - Mid 2; Proximal 4 - RV Coil
V. Triggering (BiV™ Trigger Mode)	On; Off
QuickOpt™ Timing Cycle Optimisation	Sensed/paced AV delay, interventricular pace
V-V Timing	Simultaneous**; RV First; LV First
Interventricular Pace Delay (ms)	RV First 10-80 / LV First 15-80 in increments of 5
Ventricular Sensing	RV only (not programmable)
Ventricular Pacing Chamber	RV only; biventricular
Negative AV Hysteresis/Search (ms)	Off; -10 to -120
Shortest AV Delay (ms)	25-120
AF Management	
AF Suppression™ Pacing	On; Off
No. of Overdrive Pacing Cycles	15-40 in steps of 5
Maximum AF Suppression Rate	80-150 min^{-1}
Sensing/Detection	
Sense*Ability*™ Technology	Automatic Sensitivity Control adjustment for atrial and ventricular events
Low Frequency Attenuation	On; Off
Threshold Start	(Post-Sensed; Atrial) 50; 62,5; 75; 100%; (Post-Paced; Atrial) 0,2-3,0 mV; (Post-Sensed; Ventricular) 50; 62,5; 75; 100%; (Post-Paced; Ventricular) Auto; 0,2-3,0 mV
Decay Delay	(Post-Sense/Post-Pace; Atrial/Ventricular) 0-220
Ventricular Sense Refractory (ms)	125; 157
Detection Zones	VT-1; VT-2; VF
SVT Discriminators	AV Rate Branch; Sudden Onset; Interval Stability; Morphology Discrimination (MD) with Manual or Automatic Template Update
Reconfirmation	Continuous sensing during charging
Antitachycardia Pacing Therapy	
ATP Configurations	Ramp; Burst; Scan; 1 or 2 schemes per zone
ATP in VF Zone	ATP While Charging; ATP Prior to Charging; Off
ATP Upper Rate Cutoff	150-300 bpm
Burst Cycle Length	Adaptive; Readaptive or Fixed
Min. Burst Cycle Length (ms)	150-400 in increments of 5
Number of Bursts/Stimuli	1-15 with 2-20 Stimuli
Add Stimuli per Burst	On; Off
High-Voltage Therapy	
High-Voltage Output Mode	Fixed Pulse Width; Fixed Tilt
Waveform	Biphasic; Monophasic
RV Polarity	Cathode (-); Anode (+)
Electrode Configuration	RV to Can; RV to SVC/Can
Bradycardia Pacing	
Permanent Modes	Off; DDD(R); DDT(R); DDI(R); VVT(R); VVI(R); AAI(R)
Temporary Modes	Off; DDD(R); DDT(R); DDI(R); VVT(R); VVI(R); AAI(R); AAT; DOO; VOO; AOO
Rate-Adaptive Sensor	On; Off; Passive
Programmable Rate and Delay Parameters	Off; Base Rate (min^{-1}); Rest Rate (min^{-1}); Maximum Tracking Rate (min^{-1}) Maximum Sensor Rate (min^{-1}); Paced AV Delay (ms); Sensed AV Delay (ms); Rate Responsive AV Delay; Pulse Amplitude (Atrial; RV and LV) (V); Pulse Width (Atrial; RV and LV) (ms); Hysteresis Rate (min^{-1}); Rate Hysteresis with Search
Auto Mode Switch (AMS)	Off; DDI(R); DDT(R); VVI(R); VVT(R)
AMS Detection Rate (min^{-1})	110-300
AMS Base Rate	40; 45; ...135
Auto PMT Detection/Termination	A Pace on PMT; Off; Passive
Rate Responsive PVARP/VREF	Off; Low; Medium; High
Ventricular Intrinsic Preference (VIP™)	Off; 50-200 (50-150 in increments of 25; 160-200 in increments of 10)
BiVCap™ Confirm; LVCap™ Confirm; RVCap™ Confirm	Setup; On; Monitor; Off
ACap™ Confirm	On; Monitor; Off

Post-Therapy Pacing (Independently programmable from Bradycardia and ATP)	
Post-Shock Pacing Mode	Off; AAI; VVI; DDI; or DDD
Post-Shock Base Rate (min^{-1})	30-100 in increments of 5
Post-Shock Pacing Duration (min)	Off; 0,5; 1; 2,5; 5; 7,5; or 10
Device Testing/Induction Methods	
DC Fibber™ Pulse Duration (sec)	0,5-5,0
Burst Fibber Cycle Length (ms)	20-100
Noninvasive Programmed Stimulation (NIPS)	2-25 stimuli with up to three extrastimuli
Patient Notifiers	
Programmable Notifiers (On; Off)	Device at ERI; Charge Time Limit Reached; Possible HV Circuit Damage; Atrial Lead Impedance Out of Range; RV Lead Impedance Out of Range; LV Lead Impedance Out of Range; High-Voltage Lead Impedance Out of Range; AT/AF Burden; V Rate During AT/AF; % V pacing; CorVue™ Congestion Trigger
Device Reset	On
Entry into Backup VVI Mode	On
Vibration Duration (sec)	2; 4; 6; 8; 10; 12; 14; 16
Number of Vibrations per Notification	2
Number of Notifications	1-16
Time Between Notifications (hours)	10; 22
Electrograms and Diagnostics	
Stored Electrograms	Up to 45 minutes; including up to one minute programmable pre-trigger data per VT/VF diagnosis/detection electrograms; triggers include diagnosis; therapy; atrial episode; PMT termination; PC shock delivery; noise reversion; magnet reversion; and morphology template verification
Therapy Summary	Diagram of therapies delivered
Episodes Summary	Directory listing of up to 60 episodes with access to more details including stored electrograms
Lifetime Diagnostics	History of bradycardia events and device-initiated charging
AT/AF Burden Trend	Trend data and counts
Ventricular HV Lead Impedance Trend	Multi-Vector Trend Data
Histograms	Event Histogram; AV Interval Histogram; Mode Switch Duration Histogram; Peak Filtered Rate Histogram; Atrial Heart Rate Histogram; Ventricular Heart Rate Histogram; AT/AF Burden; Exercise and Activity Trending; V Rates During AMS
PMT Data	Information regarding PMT detections
Real-Time Measurements (RTM)	Pacing lead impedances; high-voltage lead impedances; signal amplitudes
CorVue™ Congestion Monitoring	On; Off
CorVue Congestion Trigger	8-18 days

*QHR is a trademark of Greatbatch, LTD.
**LV first with 10 ms interventricular delay.

Customer Support: 46-8-474-4756

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Devices depicted may not be available in all countries. Check with your St. Jude Medical representative for product availability in your country. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies.

Item GMCRM766EN

GMCRM766EN

ST. JUDE MEDICAL
MORE CONTROL. LESS RISK.